Acumen Pharmaceuticals IncQ) expected to post a loss of 52 cents a share - Earnings Preview
Acumen Pharmaceuticals IncQ) is expected to report a loss of 52 cents per share for the quarter ending June 30, 2025, with no change in quarterly revenue. Analysts have a strong buy rating on the stock, with a median 12-month price target of $10.00, significantly above its last closing price of $1.42. The mean earnings estimate has risen by 15.3% in the last three months. Previous quarterly performances show a trend of missed estimates.
- Acumen Pharmaceuticals Inc (ABOS.OQ) (ABOS.O) is expected to
show no change in quarterly revenue when it reports results on August 12 for the period ending June 30 2025
- LSEG’s mean analyst estimate for Acumen Pharmaceuticals Inc is for a loss of 52 cents per share.
- The current average analyst rating on the shares is “strong buy” and the breakdown of recommendations is 6 “strong buy” or “buy,” no “hold” and no “sell” or “strong sell.”
- The mean earnings estimate of analysts had risen by about 15.3% in the last three months.
- Wall Street’s median 12-month price target for Acumen Pharmaceuticals Inc is $10.00, about 85.8% above its last closing price of $1.42 Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2025 -0.41 -0.45 -0.48 Missed -5.7
Dec. 31 2025 -0.48 -0.62 Missed -29.2
Sep. 30 2024 -0.41 -0.36 -0.50 Missed -37
Jun. 30 2024 -0.28 -0.28 -0.34 Missed -21.4
Mar. -0.26 -0.26 -0.25 Beat 3.8
31 2024
Dec. 31 2023 -0.30 -0.26 -0.28 Missed -7.7
Sep. 30 2023 -0.27 -0.27 -0.24 Beat 9.8
Jun. 30 2023 -0.34 -0.35 -0.28 Beat 19.1
This summary was machine generated August 8 at 15:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
